- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01481649
Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure
April 13, 2016 updated by: The University of Hong Kong
Risk of Hepatitis B Reactivation After Hematopoietic Stem Cell Transplantation in Donors and Recipients With Prior HBV Exposure
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing hematopoietic stem cell transplantation (HSCT).
Study Overview
Status
Completed
Conditions
Detailed Description
Occult hepatitis B virus (HBV) reactivation has been documented in bone marrow transplantation recipients who are hepatitis B surface antigen (HBsAg)-negative but with serologic evidence of prior exposure to HBV.
However detailed prospective studies documenting the incidence of reactivation and the virologic and serologic kinetics of reactivation are lacking.
The investigators prospective study proposes to follow-up 50 such bone marrow transplant recipients with all serologic and virologic parameters monitored every 4 weeks.
Patients with detectable HBV DNA will be started on nucleoside analogue therapy.
The optimal method and duration of monitoring will also be determined from our study.
Study Type
Observational
Enrollment (Actual)
69
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong
- Department of Medicine, the University of Hong Kong, Queen Mary Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients referred for hematopoietic stem cell transplantation (HSCT) in Hong Kong
Description
Inclusion Criteria:
- Documented HBsAg-negative HSCT recipient with or without antibody to the hepatitis B surface antigen (anti-HBs).
- Documented anti-HBc (total)-positive.
Exclusion Criteria:
- Concomitant liver diseases including chronic hepatitis C and D infection, Wilson's disease, autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
- Significant alcohol intake (>30 grams per day)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
HBsAg-negative, anti-HBc-positive
HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HBV reactivation (defined as detectable HBV DNA >20 IU/mL)
Time Frame: 2 years
|
From date of hematopoietic stem cell transplantation (HSCT) to 2 years after HSCT.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wai-Kay Seto, MRCP, The University of Hong Kong
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
February 1, 2015
Study Completion (Actual)
February 1, 2016
Study Registration Dates
First Submitted
November 24, 2011
First Submitted That Met QC Criteria
November 28, 2011
First Posted (Estimate)
November 29, 2011
Study Record Updates
Last Update Posted (Estimate)
April 14, 2016
Last Update Submitted That Met QC Criteria
April 13, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HKCTR-1422 (Registry Identifier: HKU CTC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exposure to Hepatitis B Virus
-
The University of Hong KongCompletedExposure to Hepatitis B VirusHong Kong
-
Vaxine Pty LtdFlinders Medical CentreCompletedExposure to Hepatitis B VirusAustralia
-
Taipei Veterans General Hospital, TaiwanUnknownRheumatoid Arthritis | Exposure to Hepatitis B Virus | Hepatitis B ReactivationTaiwan
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Yonsei UniversityCompletedThe Difficult-to-treat Chronic Hepatitis BKorea, Republic of
-
ANRS, Emerging Infectious DiseasesAin Shams University; Institut Pasteur; Conservatoire national des Arts et MétiersUnknownExposure to Hepatitis C VirusEgypt
-
The First Affiliated Hospital of Zhengzhou UniversityNational Natural Science Foundation of China; The Affiliated Nanjing Drum Tower... and other collaboratorsNot yet recruitingChronic Hepatitis B | Efficacy | Safety | Hepatitis B Virus | Mother-to-Child Transmission | Tenofovir Alafenamide Fumarate
-
Southeast University, ChinaUnknownHepatitis B Virus | Mother to Child TransmissionChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknownChronic Hepatitis B | Mother-to-child Block | Antiviral TreatmentChina
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... and other collaboratorsUnknownLiver Cirrhosis Due to Hepatitis B VirusChina